Single nucleotide polymorphisms of HSP90AA1 gene influence response of SLE patients to glucocorticoids treatment

[1]  Jun-Sing Wang,et al.  Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. , 2015, Rheumatology.

[2]  M. Ffrench,et al.  Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review , 2014, SpringerPlus.

[3]  I. Yaylim,et al.  The significance of HSP90AA1, HSP90AB1 and HSP90B1 gene polymorphisms in a Turkish population with non-small cell lung cancer. , 2014, Anticancer research.

[4]  D. Ye,et al.  Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: A prospective cohort study , 2013, Autoimmunity.

[5]  D. Ye,et al.  Impact of Environmental Factors on Efficacy of Glucocorticoids in Chinese Population with Systemic Lupus Erythematosus , 2013, Inflammation.

[6]  S. Nelson,et al.  Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2 , 2013, Clinical Cancer Research.

[7]  Xiangliang Zhang,et al.  High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric Cancer , 2013, PloS one.

[8]  Li Li,et al.  Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells , 2012, Molecular Biology Reports.

[9]  Peisong Chen,et al.  Nuclear HSP90 regulates the glucocorticoid responsiveness of PBMCs in patients with idiopathic nephrotic syndrome. , 2012, International immunopharmacology.

[10]  H. Shukla,et al.  Role of Hsp90 in Systemic Lupus Erythematosus and Its Clinical Relevance , 2012, Autoimmune diseases.

[11]  Samuel K. Shimp,et al.  Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus , 2012, Cellular and Molecular Immunology.

[12]  Xue-Qing Yu,et al.  Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus , 2012, Clinical Rheumatology.

[13]  A. Ventura,et al.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. , 2011, World journal of gastroenterology.

[14]  Y. Shoenfeld,et al.  The geoepidemiology of systemic lupus erythematosus. , 2010, Autoimmunity reviews.

[15]  Glinda S Cooper,et al.  Understanding the epidemiology and progression of systemic lupus erythematosus. , 2010, Seminars in arthritis and rheumatism.

[16]  J. Piette,et al.  Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? , 2010, Joint, bone, spine : revue du rhumatisme.

[17]  C. Brinckerhoff,et al.  Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. , 2009, Journal of autoimmunity.

[18]  J. Harley,et al.  Recent insights into the genetic basis of systemic lupus erythematosus , 2009, Genes and Immunity.

[19]  E. Sternberg,et al.  Neuroendocrine-Immune Interactions in Rheumatoid Arthritis: Mechanisms of Glucocorticoid Resistance , 2008, Neuroimmunomodulation.

[20]  G. Chrousos,et al.  Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. , 2008, The Journal of clinical endocrinology and metabolism.

[21]  D. Picard,et al.  The glucocorticoid responses are shaped by molecular chaperones , 2007, Molecular and Cellular Endocrinology.

[22]  C. Cooper,et al.  Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population‐based case–control study , 2007, Journal of internal medicine.

[23]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[24]  I. Adcock,et al.  Update on glucocorticoid action and resistance. , 2006, The Journal of allergy and clinical immunology.

[25]  B. Cronstein.  Pharmacogenetics in the rheumatic diseases , 2004, Bulletin of the NYU hospital for joint diseases.

[26]  Shaoxian Hu,et al.  The expression of molecular chaperone HSP90 and IL-6 in patients with systemic lupus erythematosus , 2006, Journal of Huazhong University of Science and Technology.

[27]  Bin Chen,et al.  The HSP90 family of genes in the human genome: insights into their divergence and evolution. , 2005, Genomics.

[28]  P. Murphy,et al.  Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention , 2005, Leukemia.

[29]  K. Saag.  Glucocorticoid use in rheumatoid arthritis , 2002, Current rheumatology reports.

[30]  Y. Nasuhara,et al.  Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. , 1996, British journal of pharmacology.

[31]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[32]  Y. Nasuhara,et al.  Ligand‐induced differentiation of glucocorticoid receptor (GR) trans‐repression and transactivation: preferential targetting of NF‐κB and lack of I‐κB involvement , 1999, Biochemical Society transactions.

[33]  D. Gladman,et al.  Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. , 1995, The Journal of rheumatology.

[34]  C. Malchoff,et al.  Glucocorticoid Resistance , 2020, Definitions.

[35]  G. Chrousos,et al.  5 Glucocorticoid resistance , 1994 .

[36]  M. Merrell,et al.  Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. , 1955, Journal of chronic diseases.